Bunnik, The Netherlands, 17 September 2007. AM-Pharma B.V., the biopharmaceutical company developing improved endogenous proteins to combat disease, today announced the appointment of Erik van den Berg as Chief Business Officer.
Erik van den Berg MSc MBA, joins from Organon, where he was leading the global
biotech business development efforts. Prior to joining Organon, he worked in
business and corporate development with biotech company IsoTis and as management
consultant at Arthur D. Little. Erik has been involved in the execution of over
20 transactions and partnerships.
Bart Wuurman, CEO commented: “We expect to out-license our products to
world-wide development and marketing partners once we have generated further
clinical proof of safety and efficacy of our products in Phase II trials. Therefore
we are very pleased that Erik, who has outstanding experience with product licensing
and corporate development, has joined our team to fill the key position of Chief
Business Officer.”
Erik van den Berg added: “I am excited about joining the AM-Pharma team. The two acute hospital care products AM-Pharma is developing, which address large markets, are becoming increasingly attractive for partnering as more Phase II data becomes available.”
Download this press release (61 kB, pdf)
Notes to editors:
About AM-Pharma www.am-pharma.com
AM-Pharma is a biopharmaceutical company focused on the preclinical and clinical
development of novel compounds in the field of acute hospital care. All its
products are based on endogenous molecules which have been optimised to combat
disease.
AM-Pharma recently announced positive results in two Phase IIa studies with Alkaline Phosphatase in Acute Renal Failure and severe Ulcerative Colitis, whilst Phase IIa trials of its Anti-microbial Peptide hLF1-11 for the treatment of drug resistant hospital acquired bacterial infections and for treatment of systemic Candida infections are expected to start soon.
Now that Proof of Concept has been established for Alkaline phosphatase in Acute Renal Failure and Ulcerative Colitis, AM-Pharma will look for world-wide development and marketing partners for its products while further safety and efficacy data are being collected in developmental Phase II clinical trials.
AM-Pharma is based in Bunnik, The Netherlands with a staff of 20. The company, which has recently started a series C financing round, is financed by, amongst others, Forbion Capital Partners, Inventages Venture Capital and Theratase plc.
For further information, please contact
Northbank Communications
Holly Griffiths/Adam Michael
Tel: +44 (0)20 7268 3002
ampharma@northbankcommunications.com
AM-Pharma
CEO Bart Wuurman
Tel: +31 (0)30 2289222
www.am-pharma.com